Thrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levels

Basit Öğe Kaydı
dc.contributor.authorGul, Enes Elvin
dc.contributor.authorCan, Ilknur
dc.contributor.authorKayrak, Mehmet
dc.contributor.authorAbdulhalikov, Turyan
dc.contributor.authorErdogan, Halil Ibrahim
dc.contributor.authorAltunbas, Gokhan
dc.contributor.authorOzdemir, Kurtulus
dc.date.accessioned2024-02-23T13:59:26Z
dc.date.available2024-02-23T13:59:26Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractRecent studies have reported that a novel cardiac biomarker, heart-type fatty acid-binding protein (h-FABP), significantly predicts mortality inpatients with pulmonary embolism (PE) at intermediate risk. The aim of this study was to evaluate the effect of thrombolytic therapy on prognosis of the intermediate risk acute PE patients with elevated levels of h-FABP. This is non-interventional, prospective, and single-center cohort study where 80 patients (mean age 62 +/- A 17 years, 32 men) with confirmed acute PE were included. Only patients with PE at intermediate risk (echocardiographic signs of right ventricular overload but without evidence for hypotension or shock) were included in the study. h-FABP and other biomarkers were measured upon admission to the emergency department. Thrombolytic (Thrl) therapy was administered at the physician's discretion. Of the included 80 patients, 24 were h-FABP positive (30 %). 14 patients (58 %) with positive h-FABP had clinical deterioration during the hospital course and required inotropic support and 12 of these patients died. However, of 56 patients with negative test, only 7 patients worsened or needed inotropic support and five patients died during the hospital stay. Mortality of patients with PE at intermediate risk was 21 %. The 30-day mortality rate was significantly higher in h-FABP(+) patients compared to h-FABP(-) patients (9 vs. 50 %, p < 0.001). Multivariate analysis revealed h-FABP as the only 30 day mortality predictor (HR 7.81, CI 1.59-38.34, p = 0.01). However, thrl therapy did dot affect the survival of these high-risk patients. Despite, h-FABP was successful to predict 30-days mortality in patients with PE at intermediate risk; it is suggested to be failed in determining the patients who will benefit from thrl therapy.en_US
dc.identifier.doi10.1007/s11239-013-1008-7
dc.identifier.endpage489en_US
dc.identifier.issn0929-5305
dc.identifier.issn1573-742X
dc.identifier.issue4en_US
dc.identifier.pmid24264959en_US
dc.identifier.scopus2-s2.0-84899689399en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage483en_US
dc.identifier.urihttps://doi.org/10.1007/s11239-013-1008-7
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11191
dc.identifier.volume37en_US
dc.identifier.wosWOS:000334506700015en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Thrombosis And Thrombolysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectH-Fabpen_US
dc.subjectThrombolysisen_US
dc.subjectAcute Pulmonary Embolismen_US
dc.subjectTreatmenten_US
dc.titleThrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levelsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu